Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi

Leukemia and Lymphoma

Volumn 47, Issue 3, 2006, Pages 473-479

  Di Renzo, Nicola ^a   Brugiatelli, Maura ^b   Montanini, Antonella ^c   Vigliotti, Maria Luigia ^a   Cervetti, Giulia ^d   Liberati, Anna Marina ^e   Luminari, Stefano ^c   Spedini, Pierangelo ^f   Giglio, Gianfranco ^g   Federico, Massimo ^c  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b Azienda Ospedaliera Papardo   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e POLICLINICO MONTELUCE   (Italy)

^f UO di Ematologia   (Italy)

^g Ospedale A Cardarelli   (Italy)

Author keywords

Aggressive NHL; Clinical trial; Salvage therapy; ViGePP; Vinorelbine

Indexed keywords

GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PREDNISONE; PROCARBAZINE; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROCARBAZINE; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINBLASTINE;

EID: 30844456237     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500312295     Document Type: Article

References (34)

1. Armitage, J. (1993) Treatment of non-Hodgkin's lymphoma N Engl J Med, 328, pp. 1023-1030.
2. Gisselbrecht, C. (1993) [Aggressive lymphomas] La Revue du praticien, 43(13), pp. 1648-1653.
3. Vose, J and Armitage, J. (1993) What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas? Leuk Lymphoma, 10(Suppl), pp. 61-64.
4. Child, J and Johnson, S and Rule, S and Smith, G and Morgan, G and Johnson, P. (2000) FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma Leuk Lymphoma, 37(34), pp. 309-317.
5. Seymour, J and Grigg, A and Szer, J and Fox, R. (2002) Cisplatin, fludarabine, and cytarabine: A novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma Cancer, 94(3), pp. 585-593.
6. Reiser, M and Josting, A and Dias Wickramanayake, P and Draube, A and Scheid, C and Tesch, H. (1999) Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma Leuk Lymphoma, 33(34), pp. 305-312.
7. Borghaei, H and Millenson, M and Schilder, B and Alden, M and Rogatko, A and Wang, H. (2004) Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma Cancer, 101(9), pp. 2034-2041.
8. Philip, T and Guglielmi, C and Hagenbeek, A and Somers, R and Van der Lelie, H and Bron, D and Harousseau, J and (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med, 333(23), pp. 1540-1545.
9. Webb, M and Saltman, D and Connors, J and Goldie, J. (2002) A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma Leuk Lymphoma, 43(5), pp. 975-982.
10. Savage, D and Rule, S and Tighe, M and Garrett, T and Oster, M and Lee, R. (2000) Gemcitabine for relapsed or resistant lymphoma Ann Oncol, 11(5), pp. 595-597.
11. Sallah, S and Wan, J and Nguyen, N. (2001) Treatment of refractory T-cell malignancies using gemcitabine Br J Haematol, 113(1), pp. 185-187.
12. Fossa, A and Santoro, A and Hiddemann, W and Truemper, L and Niederle, N and Buksmaui, S. (1999) Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol, 17(12), pp. 3786-3792.
13. Geffen, D and Man, S. (2002) New drugs for the treatment of cancer, 1990-2001 Isr Med Assoc J, 4(12), pp. 1124-1131.
14. Balzarotti, M and Santoro, A and Tondini, C and Fornier, M and Bonadonna, G. (1996) Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma Ann Oncol, 7(9), pp. 970-972.
15. Toh, H and Sun, L and Koh, C and Aw, S. (1998) Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: A comparison with vincristine Leuk Lymphoma, 31(12), pp. 195-208.
16. Sarris, A and Psyrri, A and Hagemeister, F and Romaguera, J and McLaughlin, P and Rodriguez, M. (2000) Infusional vinorelbine in relapsed or refractory lymphomas Leuk Lymphoma, 39(34), pp. 291-299.
17. Moore, M. (1996) Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review Cancer, 78(3 Suppl), pp. 633-638.
18. Kaufmann, M and von Minckwitz, G. (1997) Gemcitabine in ovarian cancer: an overview of safety and efficacy Eur J Cancer, 33(Suppl 1), pp. S31-S33.
19. Luftner, D and Flath, B and Akrivakis, C and Grunewald, B and Mergenthaler, H and Possinger, K. (1998) Gemcitabine for palliative treatment in metastatic breast cancer J Cancer Res Clin Oncol, 124(10), pp. 527-531.
20. Stadler, W and Kuzel, T and Raghavan, D and Levine, E and Vogelzang, N and Roth, B and Dorr, F. (1997) Metastatic bladder cancer: Advances in treatment Eur J Cancer, 33(Suppl 1), pp. S23-S26.
21. Murray, N. (1997) New drugs for small-cell lung cancer Oncology (Huntingt), 11(9 Suppl 9), pp. 38-42.
22. Carney, D. (1998) New agents in the management of advanced non-small cell lung cancer Semin Oncol, 25(4 Suppl 9), pp. 83-88.
23. Green, M. (1996) Gemcitabine safety overview Semin Oncol, 23(5 Suppl 10), pp. 32-35.
24. Abbruzzese, J. (1996) Phase I studies with the novel nucleoside analog gemcitabine Semin Oncol, 23(5 Suppl 10), pp. 25-31.
25. Steward, W. (1998) Combination studies with gemcitabine in the treatment of non-small-cell lung cancer Br J Cancer, 78(Suppl 3), pp. 15-19.
26. Fagbemi, S and Stadler, W. (1998) New chemotherapy regimens for advanced bladder cancer Semin Urol Oncol, 16(1), pp. 23-29.
27. Santoro, A and Bredenfeld, H and Devizzi, L and Tesch, H and Bonfante, V and Viviani, S. (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study J Clin Oncol, 18(13), pp. 2615-2619.
28. Massoud, M and Armand, J and Ribrag, V. (2004) Procarbazine in haematology: An old drug with a new life Eur J Cancer, 40(13), pp. 1924-1927.
29. Diehl, V and Franklin, J and Pfreundschuh, M and Lathan, B and Paulus, U and Hasenclever, D. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease N Engl J Med, 348(24), pp. 2386-2395.
30. Gobbi, P and Pieresca, C and Federico, M and Di Renzo, N and Narni, F and Iannitto, E. (1993) MOPP/EBV/CAD hybrid chemotherapy with or without limited radiotherapy in advanced or unfavorably presenting Hodgkin's disease: A report from the Italian Lymphoma Study Group J Clin Oncol, 11(4), pp. 712-719.
31. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol, 17(4), pp. 1244.
32. Rodriguez-Monge, E and Cabanillas, F. (1997) Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience Hematol Oncol Clin North Am, 11(5), pp. 937-947.
33. Hanel, M and Kroger, N and Hoffknecht, M and Peters, S and Metzner, B and Fiedler, F. (2000) ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas Ann Hematol, 79(6), pp. 304-311.
34. Gutierrez, M and Chabner, B and Pearson, D and Steinberg, S and Jaffe, E and Cheson, B. (2000) Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH J Clin Oncol, 18(21), pp. 3633-3642.